
The once-daily device, bioequivalent to the existing prefilled syringe, gives adults with AChR antibody-positive generalized MG a second self-injection option.
David Lassen, chief clinical officer at Prime Therapeutics, discusses changes in store for the field of specialty pharmacy in the coming years.
David Lassen, chief clinical officer at Prime Therapeutics, discusses changes in store for the field of specialty pharmacy in the coming years.




